The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6
Open accessAbstract
UNLABELLED: alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors. The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors. METHODS: Chimeric antitenascin monoclonal antibody 81C6 (ch81C6) (10 mg) was labeled with 71-347 MBq of (211)At by use of N-succinimidyl 3-[(211)At]astatobenzoate. Eighteen patients were treated with (211)At-labeled ch81C6 ((211)At-ch81C6) administered into a surgically created resection cavity (SCRC) and then with salvage chemotherapy. Serial gamma-camera imaging and blood sampling over 24 h were performed. RESULTS: A total of 96.7% +/- 3.6% (mean +/- SD) of (211)At decays occurred in the SCRC, and the mean blood-pool percentage injected dose was < or = 0.3. No patient experienced dose-limiting toxicity, and the maximum tolerated dose was not identified. Six patients experienced grade 2 neurotoxicity within 6 wk of (211)At-ch81C6 administration; this neurotoxicity resolved fully in all but 1 patient. No toxicities of grade 3 or higher were attributable to the treatment. No patient required repeat surgery for radionecrosis. The median survival times for all patients, those with glioblastoma multiforme, and those with anaplastic astrocytoma or oligodendroglioma were 54, 52, and 116 wk, respectively. CONCLUSION: This study provides proof of concept for regional targeted radiotherapy with (211)At-labeled molecules in oncology. Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,484
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · cited 2×
“Evaluation revealed hypocellular bone marrow (,5% cellularity) with a 46, XX, t(1;20)(p13.”
BackgroundRadiobiology for the Radiologist
Fowler, J. F., & Hall, E. J. (1988) · Radiation Research · doi:10.2307/3577489 · Cited by 785
Targeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å. M., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases
Nilsson, S., Larsen, R. H., Fosså, S. D., Balteskard, L., Borch, K. W., Westlin, J.-E., Salberg, G., & Bruland, Ø. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2244 · Cited by 440
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.
Bourdon, M. A., Wikstrand, C. J., Furthmayr, H., Matthews, T. J., & Bigner, D. D. (1983) · PubMed · Cited by 373
Self-citationGaspar, L. E., Fisher, B. J., Macdonald, D. R., Leber, D. V., Halperin, E. C., Schold, S. C., & Cairncross, J. G. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)91021-e · Cited by 295
Reardon, D. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1389 · Cited by 255
Self-citation&NA;, &. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199705000-00007 · Cited by 228
The promise of targeted {alpha}-particle therapy.
Mulford, D. A., Scheinberg, D. A., & Jurcic, J. G. (2005) · PubMed · Cited by 223
Astatine-211-Labeled Radiotherapeutics An Emerging Approach to Targeted Alpha-Particle Radiotherapy
Zalutsky, M., & Vaidyanathan, G. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003399275 · Cited by 202
Self-citationReardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., Herndon, J. E., McLendon, R. E., Pegram, C. N., Provenzale, J. M., Quinn, J. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4082 · Cited by 197
Self-citationBigner, D. D., Brown, M. T., Friedman, A. H., Coleman, R. E., Akabani, G., Friedman, H. S., Thorstad, W. L., McLendon, R. E., Bigner, S. H., Zhao, X. G., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2202 · Cited by 192
Self-citationClinical impact and functional aspects of tenascin‐C expression during glioma progression
Herold‐Mende, C., Mueller, M. M., Bonsanto, M. M., Schmitt, H. P., Kunze, S., & Steiner, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10233 · Cited by 169
André, M. P. E., Henry-Amar, M., Blaise, D., Colombat, P., Fleury, J., Milpied, N. J., Cahn, J.-Y. Y., Pico, J.-L., Bastion, Y., Kuentz, M., et al. (1998) · Blood · doi:10.1182/blood.v92.6.1933 · Cited by 151
Zalutsky, M. R., Moseley, R. P., Coakham, H. B., Coleman, R. E., & Bigner, D. D. (1989) · PubMed · Cited by 151
Self-citationA microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy
Humm, J. L. (1987) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(87)90176-3 · Cited by 110
Larsen, R. H., Wieland, B. W., & Zalutsky, M. R. (1996) · Applied Radiation and Isotopes · doi:10.1016/0969-8043(95)00285-5 · Cited by 105
Self-citationAkabani, G., Reardon, D. A., Coleman, R. E., Wong, T. Z., Metzler, S. D., Bowsher, J. E., Barboriak, D. P., Provenzale, J. M., Greer, K. L., DeLong, D. M., et al. (2005) · PubMed · Cited by 93
Self-citationThe Promise of Targeted α-Particle Therapy
Mulford, D. A., Scheinberg, D. A., & Jurcic, J. G. (2005) · Journal of Nuclear Medicine · Cited by 67
Zalutsky, M. R., Stabin, M. G., Larsen, R. H., & Bigner, D. D. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(97)00060-7 · Cited by 56
Self-citationReardon, D. A., Quinn, J. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., Herndon, J. E., McLendon, R. E., Pegram, C. N., Provenzale, J. M., et al. (2006) · PubMed · Cited by 50
Self-citationMcLendon, R. E., Archer, G. E., Larsen, R. H., Akabani, G., Bigner, D. D., & Zalutsky, M. R. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00206-0 · Cited by 31
Self-citationAkabani, G., McLendon, R. E., Bigner, D. D., & Zalutsky, M. R. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03794-x · Cited by 31
Self-citation
Cited by
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Self-citationRadioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Advances in tenascin-C biology
Midwood, K. S., Hussenet, T., Langlois, B., & Orend, G. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0783-6 · Cited by 326
Jung, H.-Y., Fattet, L., & Yang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3173 · Cited by 309
Andersson, H., Cederkrantz, E., Bäck, T., Divgi, C., Elgqvist, J., Himmelman, J., Horvath, G., Jacobsson, L., Jensen, H., Lindegren, S., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.062604 · Cited by 298
Metadata
- Authors
- Zalutsky, M. R., Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Wong, T. Z., & Bigner, D. D.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2007-12-12
- Volume
- 49
- Issue
- 1
- Pages
- 30-38
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2143818728
- Cited by
- 410
- References
- 29
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.